Publications
803 results found
Zhu R, Sharif H, Laisuan W, et al., 2020, Establishing a Th2 and Tfh cell exhaustion in vitro model using TCR Signaling to test T cell anergy during immunotherapy, European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), Publisher: WILEY, Pages: 132-133, ISSN: 0105-4538
Bédard A, Antó JM, Fonseca JA, et al., 2020, Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air® App, Allergy, Vol: 75, Pages: 1672-1688, ISSN: 0105-4538
BACKGROUND: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. METHODS: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. RESULTS: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. CONCLUSIONS: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
Hoof I, Schulten V, Layhadi JA, et al., 2020, Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses, Journal of Allergy and Clinical Immunology, Vol: 146, Pages: 180-191, ISSN: 0091-6749
BACKGROUND: Immunoglobulin E (IgE) are least abundant, tightly regulated and IgE producing B cells are rare. The cellular origin and evolution of IgE responses are poorly understood. OBJECTIVE: To investigate the cellular and clonal origin of IgE memory responses following mucosal allergen exposure by sublingual immunotherapy (SLIT). METHODS: In a randomized double-blind, placebo-controlled, time-course SLIT study, peripheral blood mononuclear cells (PBMCs) and nasal biopsies were collected from forty adults with seasonal allergic rhinitis at baseline, 4, 8, 16, 28 and 52 weeks. RNA was extracted from PBMCs, sorted B cells and nasal biopsies for VH repertoire sequencing. Moreover, monoclonal antibodies were derived from single B cell transcriptomes. RESULTS: Combining VH repertoire sequencing and single cell transcriptomics yielded direct evidence of a parallel boost of two clonally and functionally related B cell subsets of short-lived IgE+ plasmablasts and IgG+ memory B cells (termed IgGE). Mucosal grass pollen allergen exposure by SLIT resulted in highly diverse IgE and IgGE repertoires. These were extensively mutated and appeared relative stable as per heavy chain isotype, somatic hypermutations and clonal composition. Single IgGE + memory B cell and IgE+ pre-plasmablast transcriptomes encoded antibodies that were specific for major grass pollen allergens and were able to elicit basophil activation at very low allergen concentrations. CONCLUSION: For the first time, we have shown that upon mucosal allergen exposure, human IgE memory resides in allergen-specific IgG+ memory B cells. These rapidly switch isotype and expand into short-lived IgE+ plasmablasts and serve as a potential target for therapeutic intervention.
Patel K, Vila-Nadal G, Shah J, et al., 2020, Is pollen-food syndrome a frequent comorbidity in adults with irritable bowel syndrome?, ALLERGY, Vol: 75, Pages: 1780-1783, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 6
Jackson DJ, Busse WW, Bacharier LB, et al., 2020, Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor <i>ACE2</i>, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 146, Pages: 203-206, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 368
Larson D, Patel P, Salapatek AM, et al., 2020, Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 145, Pages: 1585-1597, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 19
Alvaro-Lozano M, Akdis CA, Akdis M, et al., 2020, Allergen Immunotherapy in Children User’s Guide, Pediatric Allergy and Immunology, Vol: 31, Pages: 1-101, ISSN: 0905-6157
Allergen immunotherapy is a cornerstone in the treatment of allergic children. The clinical efficiency relies on a well-defined immunologic mechanism promoting regulatory T cells and downplaying the immune response induced by allergens. Clinical indications have been well documented for respiratory allergy in the presence of rhinitis and/or allergic asthma, to pollens and dust mites. Patients who have had an anaphylactic reaction to hymenoptera venom are also good candidates for allergen immunotherapy. Administration of allergen is currently mostly either by subcutaneous injections or by sublingual administration. Both methods have been extensively studied and have pros and cons. Specifically in children, the choice of the method of administration according to the patient's profile is important. Although allergen immunotherapy is widely used, there is a need for improvement. More particularly, biomarkers for prediction of the success of the treatments are needed. The strength and efficiency of the immune response may also be boosted by the use of better adjuvants. Finally, novel formulations might be more efficient and might improve the patient's adherence to the treatment. This user's guide reviews current knowledge and aims to provide clinical guidance to healthcare professionals taking care of children undergoing allergen immunotherapy.
Pfaar O, Karatzas K, Bastl K, et al., 2020, Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas-An EAACI Task Force Report, ALLERGY, Vol: 75, Pages: 1099-1106, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 30
Dua S, DOwey J, Garcia MR, et al., 2020, How Reaction Severity Is Affected By Cofactors And Repeat Challenges: A Prospective Study Of Peanut Allergic Adults, Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), Publisher: MOSBY-ELSEVIER, Pages: AB182-AB182, ISSN: 0091-6749
- Author Web Link
- Cite
- Citations: 1
Parkin R, Eguiluz-Gracia I, Jaen MT, et al., 2020, Nasal Allergen Neutralizing Antibodies Correlate Closely with Tolerated Intranasal Allergen Challenge Dose Following Grass Pollen Subcutaneous Immunotherapy in Patients with Local Allergic Rhinitis, Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI), Publisher: MOSBY-ELSEVIER, Pages: AB184-AB184, ISSN: 0091-6749
Hellings PW, Scadding G, Bachert C, et al., 2020, EUFOREA treatment algorithm for allergic rhinitis, RHINOLOGY, Vol: 58, Pages: 618-622, ISSN: 0300-0729
- Author Web Link
- Cite
- Citations: 12
Pfaar O, Agache I, de Blay F, et al., 2019, Perspectives in allergen immunotherapy: 2019 and beyond, ALLERGY, Vol: 74, Pages: 3-25, ISSN: 0105-4538
- Author Web Link
- Cite
- Citations: 87
Nasser S, Whyte AF, Durham SR, et al., 2019, Switch-over from Pharmalgen to Alutard Bee and Wasp venom in the UK, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 49, Pages: 1645-1646, ISSN: 0954-7894
- Author Web Link
- Cite
- Citations: 3
Dua S, Ruiz-Garcia M, Bond S, et al., 2019, The effect of sleep deprivation and exercise on reaction threshold in peanut-allergic adults: a randomised controlled study, Journal of Allergy and Clinical Immunology, Vol: 144, Pages: 1584-1594.e2, ISSN: 0091-6749
BACKGROUND: Peanut allergy causes severe and fatal reactions. Current food allergen labelling fails to address these risks adequately against the burden of restricting food choice for allergic individuals because of limited data on thresholds of reactivity and the influence of everyday factors. OBJECTIVE: We estimated peanut threshold doses for a UK peanut-allergic population and examined the effect of sleep deprivation and exercise. METHOD: In a crossover study, following blinded challenge, peanut-allergic participants underwent three open peanut challenges in random order: with exercise following each dose, with sleep deprivation preceding challenge, and with no intervention. Primary outcome was the threshold dose triggering symptoms (mg protein). Primary analysis estimated the difference between non-intervention challenge and each intervention in log threshold (as % change). Dose distributions were modelled deriving eliciting doses in the peanut-allergic population. RESULTS: Baseline challenges were performed in 126 subjects, 100 were randomized and 81 (mean age 25y) completed at least one further challenge. The mean (SD) threshold was 214 mg (330mg) for non-intervention challenges and this was reduced by 45% (95% confidence interval 21,61 p=0.001) and 45% (22,62 p=0.001) for exercise and sleep deprivation, respectively. Mean (95% confidence interval) estimated eliciting doses for 1% of the population were 1.5mg (0.8,2.5) during non-intervention challenge (n=81), 0.5mg (0.2,0.8) following sleep and 0.3mg (0.1,0.6) following exercise. CONCLUSION: Exercise and sleep deprivation each significantly reduce the threshold of reactivity in people with peanut allergy, putting them at greater risk of a reaction. Adjusting reference doses using these data will improve allergen risk-management and labelling to optimize protection of peanut-allergic consumers.
Penagos M, Durham SR, 2019, Duration of allergen immunotherapy for inhalant allergy, CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, Vol: 19, Pages: 594-605, ISSN: 1528-4050
- Author Web Link
- Cite
- Citations: 31
Saleh AD, Durham SR, Shamji MH, et al., 2019, PEAK NASAL INSPIRATORY FLOW AND NASAL CYTOKINES ARE USEFUL BIOMARKERS OF NASAL INFLAMMATION IN CYSTIC FIBROSIS GENE THERAPY, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A13-A13, ISSN: 0040-6376
Hj Awg Sharif H, Singh I, Kouser L, et al., 2019, Immunologic mechanisms of short-course of Lolium Perenne peptide immunotherapy: a randomized double-blind placebo-controlled trial, Journal of Allergy and Clinical Immunology, Vol: 144, Pages: 738-749, ISSN: 0091-6749
BackgroundThree-week, short-course of adjuvant-free hydrolysates of Lolium perenne peptide (LPP) immunotherapy for rhinoconjunctivitis with/without asthma over 4 physician visits is safe, well-tolerated and effective.ObjectiveTo investigate immunologic mechanisms of LPP immunotherapy in a subset of patients who participated in a Phase III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.gov NCT02560948).MethodsParticipants were randomized to receive LPP (n=21) or placebo (PL; n=11) for 3 weeks over 4 visits. Grass pollen-induced basophil, T and B cell responses were evaluated before (V2), end of treatment (V6) and after the pollen season (V8).ResultsCombined symptom and rescue medication scores (CSMS) were lower during the peak (-35.1%, P=.03) and throughout pollen season (-53.7%, P=.03) in LPP- compared to PL-treated group. CD63+ and CD203cbrightCRTH2+basophils were decreased following LPP treatment at V6 (all, P<.0001) and V8 (all, P<.001), compared to V2. No change in PL-treated group was observed. Blunting of seasonal increases of grass pollen-specific IgE was observed in LPP- but not PL-treated group. LPP immunotherapy but not PL was associated with a reduction of IL-4+ Th2 (V6, P=.02), IL-4+ (V6, P=.001;V8, P=.0095) and IL-21+ (V6, P=.0002) T follicular helper cells. Induction of FoxP3+, follicular regulatory T and IL-10+ Breg cells were observed at V6 (all, P<.05) and V8 (all, P<.05) in LPP-treated group. Induction of regulatory B cells was associated with allergen neutralizing IgG4 blocking antibodies.ConclusionFor the first time, we demonstrate that the immunological mechanisms of LPP immunotherapy are underscored by immune modulation in the T and B cell compartments which is necessary for its effect.
Bousquet J, Nhan P-T, Bedbrook A, et al., 2019, Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases-Meeting Report (Part 2), JOURNAL OF THORACIC DISEASE, Vol: 11, Pages: 4072-4084, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 9
Bousquet J, Pfaar O, Togias A, et al., 2019, 2019 ARIA Care pathways for allergen immunotherapy, ALLERGOLOGIE, Vol: 42, Pages: 404-425, ISSN: 0344-5062
- Author Web Link
- Cite
- Citations: 2
Sahiner UM, Durham SR, 2019, Hymenoptera Venom Allergy: How Does Venom Immunotherapy Prevent Anaphylaxis From Bee and Wasp Stings?, FRONTIERS IN IMMUNOLOGY, Vol: 10, ISSN: 1664-3224
- Author Web Link
- Cite
- Citations: 35
Garcia AO, Bartra J, Garcia RM, et al., 2019, Do threshold data from food challenges reflect real-life allergen exposure?, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 151-151, ISSN: 0105-4538
Layhadi JA, Sharif H, Singh I, et al., 2019, Immunomodulatory properties of lolium perenne peptides for the treatment of seasonal allergic rhinitis, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 79-79, ISSN: 0105-4538
Bousquet J, Nhan P-T, Bedbrook A, et al., 2019, Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases, JOURNAL OF THORACIC DISEASE, Vol: 11, Pages: 3633-3641, ISSN: 2072-1439
- Author Web Link
- Cite
- Citations: 8
Wheeler K, Garcia RH, Durham SR, et al., 2019, The co-existence and diagnosis of allergic & gastrointestinal symptoms in the adults with food allergy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 441-441, ISSN: 0105-4538
Lenormand M, Layhadi JA, Hu J, et al., 2019, Epigenetic changes in SATB1 gene in FoxP3+regulatory T cells reflect immune tolerance status during grass pollen subcutaneous and sublingual immunotherapy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 63-64, ISSN: 0105-4538
Parkin R, Eguiluz-Gracia I, Tang J, et al., 2019, Nasal allergen neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 119-119, ISSN: 0105-4538
Yi Y, Sharif H, Krasner-Macleod S, et al., 2019, Immunomodulation of CD4+CXCR5+PD-1+T follicular helper (Tfh) and CD4+CXCR5+PD-1+FoxP3+T follicular regulatory (Tfr) cell responses in grass pollen allergy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 199-199, ISSN: 0105-4538
Sharif H, Acharya S, Dhondalay GK, et al., 2019, Altered chromatin landscape in T follicular cells in seasonal allergic rhinitis and following allergen-specific immunotherapy, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 64-65, ISSN: 0105-4538
Layhadi JA, Thomsen I, Kappen J, et al., 2019, Broad immunoglobulin G repertoire in chronic rhinosinusitis with nasal polyps regulates pro-inflammatory IgE responses, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 53-53, ISSN: 0105-4538
Garcia RH, Donovan J, Scadding G, et al., 2019, Is Pru p 3 a relevant test for lipid transfer protein allergy in a Northern European population?, Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Publisher: WILEY, Pages: 142-142, ISSN: 0105-4538
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.